Objective To investigate sorafenib on changes in serological indicators and imaging indexes in patients with iodine-refractory differentiated thyroid cancer(RAIR-DTC).Methods A total of 40 RAIR-DTC patients from January 2020 to December 2020 were collected,and all patients were treated with sorafenib,and the clinical efficacy was analyzed.The serological indicators,immune function indexes,adverse reactions,quality of life score,apparent diffusion coefficient(ADC)values were included as comparators before and after treatment.Results Forty RAIR-DTC patients were followed up for 122-303 days.By the end of 303 days of follow-up,the objective remission rate(ORR)and disease control rate(DCR)of the disease were 60.0%and 80.0%,respectively.All patients had adverse reactions with various degree,and the incidence adverse reactions like alopecia,hypertension,hand-foot syndrome,fatigue,and diarrhea were all over 20%.The serum indexes of vascular endothelial growth factor(VEGF),neutrophil gelatinase-associated lipocalin(NGAL),thyroglobulin antibodies(TG-Ab)and thyroglobulin(TG)after treatment were significantly lower than those before treatment(P<0.05).The CD8+index after treatment was significantly higher than that before treatment,but the CD4+,CD3+and CD4+/CD8+ratio were significantly lower(P<0.05).The scores of mental health,emotional function,social function,energy,general health,somatic pain,physiological role and physiological function of the patients after treatment were significantly evaluated than those before treatment(P<0.05).The ADC value of the patients showed a continuous upward trend.Conclusion Sorafenib can significantly reduce serological indicators and improve immune function in RAIR-DTC patients.There is a relatively high DCR,ideal treatment effect,great improved quality of life despite the presence of adverse reactions.Meantime,the ADC value by imaging examination can play an objective evaluation role to a certain extent,and provide some guidance for follow-up treatment in these patients.
iodine-refractory differentiated thyroid cancersorafenibserologyimmune functionimagingdisease control rate
NETL
NSTL
万方数据
